<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54872">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391805</url>
  </required_header>
  <id_info>
    <org_study_id>NP28938</org_study_id>
    <nct_id>NCT02391805</nct_id>
  </id_info>
  <brief_title>A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
  <official_title>A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, multicenter, partially double-blind, placebo-controlled study is designed
      to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral
      effects of treatment with RO6864018 in virologically suppressed participants with chronic
      HBV infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 17, 2015</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Percentage of participants with adverse events</measure>
    <time_frame>Up to 36 weeks (scheduled visits at Baseline; at Weeks 1, 2, 3, 5, 7, 9 and 12 during treatment; then at Weeks 16, 20, 24, 28, 32, and 36 during follow-up)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Peripheral blood levels of interferon (IFN)-alpha in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) and post-dose (6, 24 hours) on Days 1, 3, 7 of Week 1; on Day 1 of Weeks 3, 5, 7; and Day 6 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Peripheral blood levels of IFN-alpha in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) and post-dose (6, 24 hours) on Day 1 of Weeks 1, 2, 3, 5, 7, 12; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Peripheral blood levels of IFN-gamma-induced protein (IP)-10 in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) and post-dose (6, 24 hours) on Days 1, 3, 7 of Week 1; on Day 1 of Weeks 3, 5, 7; and Day 6 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Peripheral blood levels of IP-10 in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) and post-dose (6, 24 hours) on Day 1 of Weeks 1, 2, 3, 5, 7, 12; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Quantitative HBV deoxyribonucleic acid (DNA) level in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 7 of Week 1 and Day 1 of Weeks 3, 5, 7; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up; and at any point that breakthrough occurs (up to 36 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Quantitative HBV DNA level in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 1 of Weeks 2, 3, 5, 7; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up; and at any point that breakthrough occurs (up to 36 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Quantitative hepatitis B surface antigen (HBsAg) level in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 7 of Week 1 and Day 1 of Weeks 3, 5, 7; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Quantitative HBsAg level in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 1 of Weeks 2, 3, 5, 7; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with loss of HBsAg in QOD dosing cohorts</measure>
    <time_frame>Baseline; on Day 7 of Week 12; then at Week 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with loss of HBsAg in QWk dosing cohorts</measure>
    <time_frame>Baseline; on Day 7 of Week 12; then at Week 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with loss of hepatitis B envelope antigen (HBeAg) in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 7 of Week 1 and Day 1 of Weeks 3, 5, 7; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with loss of HBeAg in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 1 of Weeks 2, 3, 5, 7; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with HBsAg seroconversion (antibody to HBsAg [anti-HBs] positive status and loss of HBsAg) in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 7 of Week 1 and Day 1 of Week 5; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with HBsAg seroconversion (anti-HBs positive status and loss of HBsAg) in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 1 of Weeks 2, 5; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with HBeAg seroconversion (antibody to HBeAg [anti-HBe] positive status and loss of HBeAg) in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 7 of Week 1 and Day 1 of Week 5; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of participants with HBeAg seroconversion (anti-HBe positive status and loss of HBeAg) in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) on Day 1 of Weeks 2, 5; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum observed plasma concentration (Cmax) of RO6864018 metabolite in every other day (QOD) dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Days 1, 7 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of RO6864018 metabolite in every week (QWk) dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Day 1 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 2, 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to maximum observed plasma concentration (Tmax) of RO6864018 metabolite in QOD dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Days 1, 7 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax of RO6864018 metabolite in QWk dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Day 1 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 2, 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve extrapolated to infinity (AUCinf) of RO6864018 metabolite in QOD dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Days 1, 7 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUCinf of RO6864018 metabolite in QWk dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Day 1 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 2, 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve up to the last measurable concentration (AUClast) of RO6864018 metabolite in QOD dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Days 1, 7 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUClast of RO6864018 metabolite in QWk dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Day 1 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 2, 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Half-life (t1/2) of RO6864018 metabolite in QOD dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Days 1, 7 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: T1/2 of RO6864018 metabolite in QWk dosing cohorts</measure>
    <time_frame>Pre-dose (0 hours) and post-dose (0.25, 1, 2, 4, 6, 8, 12, 24 hours) on Day 1 of Week 1; pre-dose (0 hours) and post-dose (1, 2-4 hours) on Day 1 of Weeks 2, 3, 5, 7, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Peripheral blood levels of neopterin in QOD dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) and post-dose (6, 24 hours) on Days 1, 3, 7 of Week 1; on Day 1 of Weeks 3, 5, 7; and Day 6 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Peripheral blood levels of neopterin in QWk dosing cohorts</measure>
    <time_frame>Baseline; pre-dose (0 hours) and post-dose (6, 24 hours) on Day 1 of Weeks 1, 2, 3, 5, 7, 12; on Day 7 of Week 12; then at Weeks 16, 20, 24, 28, 32, 36 during follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Placebo, QOD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, QWk</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO6864018, 1200 mg QOD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO6864018 1200 milligrams (mg) PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO6864018, 1200 mg QWk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO6864018, 800 mg QOD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO6864018, 800 mg QWk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir will be administered as per local labeling.</description>
    <arm_group_label>Placebo, QOD</arm_group_label>
    <arm_group_label>Placebo, QWk</arm_group_label>
    <arm_group_label>RO6864018, 1200 mg QOD</arm_group_label>
    <arm_group_label>RO6864018, 1200 mg QWk</arm_group_label>
    <arm_group_label>RO6864018, 800 mg QOD</arm_group_label>
    <arm_group_label>RO6864018, 800 mg QWk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.</description>
    <arm_group_label>Placebo, QOD</arm_group_label>
    <arm_group_label>Placebo, QWk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6864018</intervention_name>
    <description>Participants will be administered RO6864018 as 200-mg PO capsules at a daily dosage of 800 or 1200 mg, either QOD or QWk for 12 weeks of treatment.</description>
    <arm_group_label>RO6864018, 1200 mg QOD</arm_group_label>
    <arm_group_label>RO6864018, 1200 mg QWk</arm_group_label>
    <arm_group_label>RO6864018, 800 mg QOD</arm_group_label>
    <arm_group_label>RO6864018, 800 mg QWk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir will be administered as per local labeling.</description>
    <arm_group_label>Placebo, QOD</arm_group_label>
    <arm_group_label>Placebo, QWk</arm_group_label>
    <arm_group_label>RO6864018, 1200 mg QOD</arm_group_label>
    <arm_group_label>RO6864018, 1200 mg QWk</arm_group_label>
    <arm_group_label>RO6864018, 800 mg QOD</arm_group_label>
    <arm_group_label>RO6864018, 800 mg QWk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 to 65 years of age

          -  Chronic hepatitis B infection

          -  Positive test for HBsAg for more than 6 months prior to randomization

          -  HBsAg titer greater than or equal to (&gt;/=) 250 international units per milliliter
             (IU/mL) at Screening

          -  Treatment with any nucleoside/nucleotide analogue for &gt;/= 1 year with ongoing
             entecavir or tenofovir treatment at randomization and for at least 3 months prior to
             randomization

          -  HBV DNA less than (&lt;) 90 IU/mL for at least the preceding 6 months

          -  HBeAg positive at randomization and for at least 6 months prior to randomization

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Documented history of HBV genotype D

          -  History or other evidence of bleeding from esophageal varices

          -  History of decompensated liver disease, chronic liver disease other than HBV
             infection, or any evidence of metabolic liver disease

          -  Positive test for hepatitis A, hepatitis C, or human immunodeficiency virus (HIV)

          -  Documented history of hepatitis D infection

          -  History of or suspicion of hepatocellular carcinoma

          -  History of immunologically mediated disease

          -  History of organ transplantation

          -  History of thyroid disease

          -  Significant acute infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang; Medicine</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3248</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>00112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
